| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VPH Stock Overview
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada.
Valeo Pharma Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.56 |
| 52 Week High | CA$0.97 |
| 52 Week Low | CA$0.45 |
| Beta | 3 |
| 1 Month Change | 13.13% |
| 3 Month Change | -9.68% |
| 1 Year Change | -36.36% |
| 3 Year Change | 0% |
| 5 Year Change | n/a |
| Change since IPO | -13.85% |
Recent News & Updates
Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%
The analysts covering Valeo Pharma Inc. ( TSE:VPH ) delivered a dose of negativity to shareholders today, by making a...
Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts
It's been a pretty great week for Valeo Pharma Inc. ( TSE:VPH ) shareholders, with its shares surging 12% to CA$0.56 in...
Shareholder Returns
| VPH | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | -6.7% | -1.3% | -0.8% |
| 1Y | -36.4% | -34.9% | -5.0% |
Return vs Industry: VPH underperformed the Canadian Healthcare industry which returned -34.9% over the past year.
Return vs Market: VPH underperformed the Canadian Market which returned -5% over the past year.
Price Volatility
| VPH volatility | |
|---|---|
| VPH Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: VPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: VPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 100 | Steve Saviuk | https://www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson’s Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic.
Valeo Pharma Fundamentals Summary
| VPH fundamental statistics | |
|---|---|
| Market Cap | CA$45.75m |
| Earnings (TTM) | -CA$21.60m |
| Revenue (TTM) | CA$18.06m |
2.5x
P/S Ratio-2.1x
P/E RatioIs VPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPH income statement (TTM) | |
|---|---|
| Revenue | CA$18.06m |
| Cost of Revenue | CA$12.13m |
| Gross Profit | CA$5.93m |
| Other Expenses | CA$27.53m |
| Earnings | -CA$21.60m |
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 32.83% |
| Net Profit Margin | -119.62% |
| Debt/Equity Ratio | -655.2% |
How did VPH perform over the long term?
See historical performance and comparisonValuation
Is VPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VPH?
Other financial metrics that can be useful for relative valuation.
| What is VPH's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CA$45.75m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | -4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VPH's PS Ratio compare to its peers?
| VPH PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.1x | ||
TCAN TransCanna Holdings | 2x | n/a | CA$7.8m |
BLMH Bloom Health Partners | 0.3x | n/a | CA$7.7m |
HLS HLS Therapeutics | 5x | 35.2% | CA$390.0m |
XCX Greenrise Global Brands | 13.1x | n/a | CA$8.5m |
VPH Valeo Pharma | 2.5x | 36.0% | CA$45.8m |
Price-To-Sales vs Peers: VPH is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (5.1x).
Price to Earnings Ratio vs Industry
How does VPH's PE Ratio compare vs other companies in the CA Healthcare Industry?
Price-To-Sales vs Industry: VPH is expensive based on its Price-To-Sales Ratio (2.5x) compared to the Canadian Healthcare industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is VPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.5x |
| Fair PS Ratio | 2.4x |
Price-To-Sales vs Fair Ratio: VPH is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).
Share Price vs Fair Value
What is the Fair Price of VPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VPH (CA$0.56) is trading below our estimate of fair value (CA$17.04)
Significantly Below Fair Value: VPH is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VPH's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Valeo Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
5/6Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
66.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: VPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VPH is expected to become profitable in the next 3 years.
Revenue vs Market: VPH's revenue (36% per year) is forecast to grow faster than the Canadian market (6.5% per year).
High Growth Revenue: VPH's revenue (36% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Valeo Pharma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-52.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VPH is currently unprofitable.
Growing Profit Margin: VPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VPH is unprofitable, and losses have increased over the past 5 years at a rate of 52.5% per year.
Accelerating Growth: Unable to compare VPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VPH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-68.2%).
Return on Equity
High ROE: VPH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is Valeo Pharma's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: VPH has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: VPH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VPH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is Valeo Pharma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VPH has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Steve Saviuk (63 yo)
19.5yrs
Tenure
CA$259,344
Compensation
Mr. Steven Saviuk, also known as Steve, CA, serves as Independent Director at Cluny Capital Corp. since April 15, 2021. He serves as Vice Chairman of Valeo Pharma Inc. since January 18, 2021 and is its Dir...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD201.26K) is about average for companies of similar size in the Canadian market ($USD191.19K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: VPH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Experienced Board: VPH's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Top Shareholders
Company Information
Valeo Pharma Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Valeo Pharma Inc.
- Ticker: VPH
- Exchange: TSX
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: CA$45.755m
- Shares outstanding: 81.71m
- Website: https://www.valeopharma.com
Number of Employees
Location
- Valeo Pharma Inc.
- 16667 Hymus Boulevard
- Kirkland
- Quebec
- H9H 4R9
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/04 00:00 |
| End of Day Share Price | 2022/07/04 00:00 |
| Earnings | 2022/04/30 |
| Annual Earnings | 2021/10/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.